VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions May 27, 2020
VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP) May 18, 2020
VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19 Apr 28, 2020
VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million Mar 25, 2020
VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder Feb 20, 2020
VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview Feb 13, 2020
VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects Feb 11, 2020
VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients Jan 30, 2020
VistaGen and Baylor College of Medicine Announce Successful Results of First-Step Target Engagement Study with VistaGen's AV-101 Focused on Treating Suicidal Ideation in Veterans Dec 19, 2019
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder Dec 10, 2019
